Nutritional compositions, products comprising same and uses thereof

Abstract

The present invention relates to a nutritional composition, products comprising the same and uses thereof. The nutritional composition comprises partially hydrolyzed protein and medium-long chain fatty acid triglycerides, wherein the weight ratio of the medium-long chain fatty acid triglycerides to the partially hydrolyzed protein is 0.067-1.33. The nutritional composition has a synergistic effect in improving intestinal colic and / or abdominal distension. The present invention also relates to the use of the nutritional composition in the manufacture of a product for improving intestinal colic and / or abdominal distension.

Description

Technical Field

[0001] This disclosure relates to nutritional compositions, products containing the same, and their uses. Background Technology

[0002] Colic and bloating are common functional gastrointestinal symptoms with a high incidence in both infants and adults. Infantile colic is mainly characterized by paroxysmal, persistent crying without obvious cause, often accompanied by abdominal distension, increased flatulence, and other signs of discomfort, with an incidence of approximately 5%–25%. It may be related to factors such as immature gastrointestinal development, food intolerance, food allergies, or intestinal gas accumulation, but currently there is no clear cause or universally accepted effective prevention or treatment method, causing significant distress to infants and their caregivers.

[0003] In adults, symptoms such as bloating and flatulence are also common and closely related to lifestyle, psychological stress, and functional gastrointestinal disorders. Related studies show that more than half of the population has experienced varying degrees of gastrointestinal discomfort, with bloating being one of the most common symptoms, suggesting that such problems have a wide range of health impacts.

[0004] Currently, interventions for colic and bloating mainly include behavioral adjustments, medication, or medical nutrition support. However, caution is needed when administering medication to infants and young children, and long-term medication use in adults may have side effects or compliance issues. Existing nutritional intervention programs are mostly compound formulas, and their mechanisms of action are not yet clear, leaving room for improvement.

[0005] Therefore, it is of great significance to develop a method to improve intestinal colic and / or bloating. Summary of the Invention

[0006] This invention was made in view of the above-mentioned problems existing in the prior art.

[0007] The first aspect of the present invention provides a nutritional composition comprising partially hydrolyzed protein and medium- and long-chain fatty acid triglycerides, wherein the weight ratio of the medium- and long-chain fatty acid triglycerides to the partially hydrolyzed protein is 0.067-1.33.

[0008] The applicant found that when the nutritional composition contains a defined weight ratio of medium- and long-chain fatty acid triglycerides to partially hydrolyzed protein, it has a synergistic effect in improving intestinal colic and / or bloating.

[0009] A second aspect of the present invention provides a product comprising the nutritional composition described in the first aspect of the present invention.

[0010] A third aspect of the present invention provides the use of the nutritional composition according to the first aspect of the present invention in the preparation of products for improving intestinal colic and / or bloating. Attached Figure Description

[0011] Figure 1 The graph shows the total movement distance of zebrafish after sample treatment. Compared with the model control group, * indicates p < 0.05, ** indicates p < 0.01, and *** indicates p < 0.001; compared with Comparative Example 1, ! indicates p < 0.05, !! indicates p < 0.01, and !!! indicates p < 0.001; compared with Comparative Example 2, ## indicates p < 0.01; compared with Comparative Example 4, $$ indicates p < 0.01, $$$ indicates p < 0.001; compared with Comparative Example 5, && indicates p < 0.01; and compared with Comparative Example 6, + indicates p < 0.05.

[0012] Figure 2 The image shows typical zebrafish behavior after sample treatment, where the black line represents the distance of slow movement, the green line represents the distance of medium movement, and the red line represents the distance of fast movement.

[0013] Figure 3 The graph shows the statistical distribution of zebrafish intestinal lumen area after sample treatment. Compared with the model control group, * indicates p < 0.05, ** indicates p < 0.01, and *** indicates p < 0.001; compared with Comparative Example 1, !! indicates p < 0.01, and !!! indicates p < 0.001; compared with Comparative Example 2, ## indicates p < 0.01; compared with Comparative Example 4, $ indicates p < 0.05, $$ indicates p < 0.01; compared with Comparative Example 5, && indicates p < 0.01; and compared with Comparative Example 6, + indicates p < 0.05.

[0014] Figure 4 This is a graph showing the measurement of the intestinal lumen area of ​​zebrafish after sample processing. Detailed Implementation

[0015] The following definitions are provided to enable those skilled in the art to understand the invention. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. Preferred materials and methods are described herein, but any methods and materials similar to or equivalent to those described herein may be used in the practice of testing the invention. It should also be understood that the terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting.

[0016] Unless otherwise indicated or defined, all terms used have their ordinary meaning in the art as would be understood by those skilled in the art. Furthermore, unless otherwise stated, all methods, steps, techniques, and operations not specifically detailed herein may be performed and have been carried out in a manner known per se as would be understood by those skilled in the art.

[0017] Nutritional composition

[0018] The first aspect of the present invention provides a nutritional composition comprising partially hydrolyzed protein and medium- and long-chain fatty acid triglycerides, wherein the weight ratio of the medium- and long-chain fatty acid triglycerides to the partially hydrolyzed protein is 0.067-1.33.

[0019] The applicant discovered that when the nutritional composition contains a specified weight ratio of medium- and long-chain fatty acid triglycerides and partially hydrolyzed protein, it has a synergistic effect in improving intestinal colic. Additionally, it may also have a synergistic effect in improving bloating.

[0020] In the embodiments, the weight ratio of the medium- and long-chain fatty acid triglycerides to the partially hydrolyzed protein in the nutritional composition is 0.067, 0.07, 0.08, 0.09, 0.10, 0.11, 0.12, 0.13, 0.14, 0.15, 0.16, 0.17, 0.18, 0.19, 0.20, 0.21, 0.22, 0.23, 0.24, and 0.25. 0.26, 0.27, 0.28, 0.29, 0.30, 0.33, 0.35, 0.40, 0.45, 0.50, 0.55, 0.60, 0.65, 0.66, 0.67, 0.68, 0.69, 0.70, 0.71, 0.72, 0.73, 0.74, 0.75, 0.76, 0.77, 0.78, 0.79, 0.80 0.81, 0.82, 0.83, 0.84, 0.85, 0.86, 0.87, 0.88, 0.89, 0.90, 0.91, 0.92, 0.93, 0.94, 0.95, 0.96, 0.97, 0.98, 0.99, 1.00, 1.01, 1.02, 1.03, 1.04, 1.05, 1.06, 1.07, 1.08, 1 The range defined by .09, 1.10, 1.11, 1.12, 1.13, 1.14, 1.15, 1.16, 1.17, 1.18, 1.19, 1.20, 1.21, 1.22, 1.23, 1.24, 1.25, 1.26, 1.27, 1.28, 1.29, 1.30, 1.31, 1.32, 1.33, or any two of them.

[0021] In some embodiments, the weight ratio of the medium- and long-chain fatty acid triglycerides to the partially hydrolyzed protein in the nutritional composition is 0.13-1.33; within this range, it has a synergistic effect in improving intestinal colic and also has a synergistic effect in improving bloating.

[0022] In some embodiments, the weight ratio of the medium- and long-chain fatty acid triglycerides to the partially hydrolyzed protein in the nutritional composition is 0.067-0.27; within this range, its synergistic effect in improving intestinal colic is more significant.

[0023] In some embodiments, the weight ratio of the medium- and long-chain fatty acid triglycerides to the partially hydrolyzed protein in the nutritional composition is 0.13-0.27; within this range, its synergistic effect in improving intestinal colic is more significant, and its synergistic effect in improving bloating is also more significant.

[0024] As used herein, the term "partially hydrolyzed protein" refers to a product obtained by partially hydrolyzing a protein to a lesser degree than complete hydrolysis. The partially hydrolyzed protein may comprise a mixture of protein fragments, polypeptides, peptides, amino acids, and / or peptones. It should be understood that partial hydrolysis does not include products obtained from complete hydrolysis of a protein consisting solely of free amino acids.

[0025] The hydrolysis process can be, for example, acid hydrolysis, alkaline hydrolysis, and / or enzymatic hydrolysis, with enzymatic hydrolysis being preferred. Unbound by any theoretical constraints, enzymatic hydrolysis offers higher selectivity at cleavage sites on protein molecules compared to acid or alkaline hydrolysis, thereby yielding protein fragments and peptides with more controllable molecular weight distribution and more stable functional properties.

[0026] The partially hydrolyzed protein may be a partially hydrolyzed animal protein and / or a partially hydrolyzed plant protein. In some embodiments, the partially hydrolyzed protein is a partially hydrolyzed plant protein selected from one or more of soy protein, pea protein, wheat protein, and rice protein. In some embodiments, the partially hydrolyzed protein is a partially hydrolyzed animal protein, such as partially hydrolyzed milk protein (i.e., partially hydrolyzed cow's milk protein), selected from whey protein, casein, or mixtures thereof, preferably whey protein. Preferably, the partially hydrolyzed protein is derived from demineralized whey powder.

[0027] In some embodiments, the degree of hydrolysis of the partially hydrolyzed protein may be 7%-25%; within this range, the nutritional composition is more effective in improving intestinal colic and / or bloating. The degree of hydrolysis of the partially hydrolyzed protein is, for example, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, or within the range defined by any two of these. Preferably, the degree of hydrolysis of the partially hydrolyzed protein is 7%-17%; within this range, the nutritional composition is more effective in improving intestinal colic and / or bloating. Preferably, the degree of hydrolysis of the partially hydrolyzed protein is 7%-15%; within this range, the nutritional composition is more effective in improving intestinal colic and / or bloating.

[0028] In some embodiments, peptides with a molecular weight >5000 Da account for 10%-80% of the mass of the partially hydrolyzed protein; within this range, the nutritional composition is more effective in improving intestinal colic and / or bloating. In the partially hydrolyzed protein, the proportion of peptides with a molecular weight >5000 Da is, for example, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, or within the range defined by any two of these. Preferably, in the partially hydrolyzed protein, peptides with a molecular weight >5000 Da account for 10%-70% by mass; within this range, the nutritional composition is more effective in improving intestinal colic and / or bloating.

[0029] In some embodiments, the proportion of peptides with a molecular weight of 1000-5000 Da in the partially hydrolyzed protein is 7%-47% by mass; within this range, the nutritional composition is more effective in relieving intestinal colic and / or bloating. The proportion of peptides with a molecular weight of 1000-5000 Da in the partially hydrolyzed protein is, for example, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, or within the range defined by any two of these. Preferably, in the partially hydrolyzed protein, peptides with a molecular weight of 1000-5000 Da account for 10%-35% by mass; within this range, the nutritional composition is more effective in improving intestinal colic and / or bloating.

[0030] In some embodiments, peptides with a molecular weight <1000 Da account for 13%-80% of the mass of the partially hydrolyzed protein; within this range, the nutritional composition is more effective in improving intestinal colic and / or bloating. In the partially hydrolyzed protein, the proportion of peptides with a molecular weight <1000 Da is, for example, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, or within the range defined by any two of these. Preferably, in the partially hydrolyzed protein, peptides with a molecular weight <1000 Da account for 15%-58% by mass; within this range, the nutritional composition is more effective in improving intestinal colic and / or bloating.

[0031] In some preferred embodiments, the degree of hydrolysis of the partially hydrolyzed protein is 7%-15%, the proportion of peptides with a molecular weight >5000 Da is 10%-70% by mass, the proportion of peptides with a molecular weight of 1000-5000 Da is 10%-35% by mass, and the proportion of peptides with a molecular weight <1000 Da is 15%-58% by mass; within this range, the nutritional composition is more effective in improving intestinal colic and / or bloating.

[0032] The partially hydrolyzed protein may be a single partially hydrolyzed protein or a mixture of two or more partially hydrolyzed proteins.

[0033] In this application, the term "medium-chain fatty acid" refers to fatty acids with 6-12 carbon atoms in their carbon chain, such as hexanoic acid, heptanoic acid, octanoic acid, nonanoic acid, decanoic acid, undecanoic acid, and dodecanoic acid. The term "long-chain fatty acid" refers to fatty acids with 14 or more carbon atoms in their carbon chain, generally 14-30 carbon atoms, such as myristic acid, palmitic acid, oleic acid, linoleic acid, stearic acid, linolenic acid, arachidonic acid, eicosapentaenoic acid, docosapentaenoic acid, and docosahexaenoic acid. The terms "medium-chain fatty acid triglyceride" and "long-chain fatty acid triglyceride" refer to the esterification products of "medium-chain fatty acids" and "long-chain fatty acids" with glycerol, respectively.

[0034] As used herein, the term "medium- and long-chain triglycerides" (MLCT) refers to a class of triglycerides that contain both medium-chain and long-chain fatty acid residues in their molecular structure. MLCTs possess different physicochemical properties, metabolic characteristics, and nutritional value from long-chain triglycerides (LCT) or medium-chain triglycerides (MCT). Studies (see, for example, Yuan Tinglan, Composition and Metabolic Characteristics of Medium- and Long-Chain Triglycerides in Breast Milk Fat [D], Jiangnan University, 2021) show that medium- and long-chain triglycerides (MLCT) are not simply equivalent to a physical mixture of long-chain triglycerides (LCT) and medium-chain triglycerides (MCT) (nor are they simply equivalent to a mixture of long-chain and medium-chain fatty acids), and the latter does not possess the physicochemical properties, metabolic characteristics, and nutritional value of the former.

[0035] According to the relevant provisions of the "Administrative Measures for New Resource Foods", MLCT is made from edible vegetable oil and medium-chain triglycerides as raw materials, through lipase transesterification reaction, and then through processes such as distillation separation, decolorization, and deodorization.

[0036] This invention does not have any particular requirements for the MLCT used; any MLCT commonly used in the art can be used. MLCT can be used in pure form or in an impure form rich in MLCT. The MLCT component contained in the nutritional composition can be a single-component MLCT (i.e., each molecular chain has the same long-chain fatty acid residues and the same medium-chain fatty acid residues) or a mixture of two or more different-component MLCTs (i.e., each molecular chain has different long-chain fatty acid residues and / or different medium-chain fatty acid residues).

[0037] In some embodiments, the MLCT used in this invention comprises C6-C 12 (e.g., C6, C7, C8, C9, C) 10 C 11 C 12 (or the range defined by either or both) fatty acid residues and C 14 -C 30 (e.g., C) 14 C 15 C 16 C 17 C 18 C 19 C 20 C 21 C 22 C 23 C 24 C 25 C 26 C 27 C 28 C 29 C30 (or the range defined by either or both) fatty acid residues. The C6-C 12 The fatty acid residues may be derived from one or more of the following: hexanoic acid, heptanoic acid, octanoic acid, nonanoic acid, decanoic acid, undecanoic acid, dodecanoic acid, etc., preferably hexanoic acid, octanoic acid, decanoic acid, and lauric acid. The C 14 -C 30 The fatty acid residues may be derived from one or more of the following: myristic acid, palmitic acid, heptadecanic acid, oleic acid, linoleic acid, stearic acid, nonadecanic acid, eicosapentaenoic acid, docosahexaenoic acid, docosapatraenoic acid, docosahexaenoic acid, tricarboxylic acid, docosapetraenoic acid, docosapatraenoic acid, docosahexaenoic acid, arachidonic acid, etc., preferably myristic acid, palmitic acid, oleic acid, linoleic acid, stearic acid, linolenic acid, arachidonic acid, eicosapentaenoic acid, docosapatraenoic acid and docosahexaenoic acid.

[0038] In some embodiments, the C6-C in the MLCT 12 Fatty acid residues on the C 14 -C 30 The weight ratio of fatty acid residues is from 0.124 to 2.000. As an example, the C6-C... 12 Fatty acid residues on the C 14 -C 30 The weight ratio of fatty acid residues may be 0.124, 0.125, 0.130, 0.140, 0.150, 0.160, 0.170, 0.180, 0.190, 0.200, 0.300, 0.400, 0.500, 0.600, 0.700, 0.800, 0.900, 1.000, 1.100, 1.200, 1.300, 1.400, 1.500, 1.600, 1.700, 1.800, 1.900, 2.000, or within the range defined by any two of these.

[0039] product

[0040] A second aspect of the present invention provides a product comprising the nutritional composition described in the first aspect of the present invention.

[0041] All descriptions above relating to the first aspect of the present invention are applicable here and will not be repeated here.

[0042] In some embodiments, the product is a drug.

[0043] In some embodiments, the drug may be any dosage form, such as a solid dosage form (granules, powders, tablets, etc.) or a liquid dosage form. Furthermore, those skilled in the art will readily understand that, depending on the dosage form and application scenario, the drug may also include various pharmaceutically permissible excipients.

[0044] The products, such as pharmaceuticals, can be prepared using methods commonly employed in the art, which will not be elaborated upon here.

[0045] In some embodiments, the content of the partially hydrolyzed protein in the product is 0.1%-50% based on the total dry weight of the product (after deducting moisture). As an example, based on the total dry weight of the product, the content of the partially hydrolyzed protein in the product is within the range defined by 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1.0%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, or any two of these.

[0046] In some embodiments, the content of medium- and long-chain fatty acid triglycerides in the product is 0.1%-30% based on the total dry weight of the product (after deducting moisture). As an example, the content of medium- and long-chain fatty acid triglycerides in the product is within the range defined by any two of the following, based on the total dry weight of the product: 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1.0%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%.

[0047] use

[0048] A third aspect of the present invention provides the use of the nutritional composition according to the first aspect of the present invention in the preparation of products for improving intestinal colic and / or bloating.

[0049] All descriptions above relating to the first and second aspects of the present invention are applicable here and will not be repeated here.

[0050] In some implementations, there are no particular limitations on the subjects for improving intestinal colic and / or bloating, and may include, for example, infants, toddlers, children, adolescents, adults, young adults, middle-aged people, and / or the elderly.

[0051] As used herein, the following terms have the following meanings.

[0052] The term "infant" refers to a person from birth to 12 months of age.

[0053] The term "toddler" refers to a person from 1 to 3 years of age.

[0054] The term "child" refers to a person from 3 to 7 years of age.

[0055] The term "adolescent" refers to a person from 7 to 17 years of age.

[0056] The term "adult" refers to a person 18 years of age or older.

[0057] The term "young adult" refers to a person from 18 to 40 years of age.

[0058] The term "middle-aged person" refers to a person from 41 to 65 years of age.

[0059] The term "elderly person" or "senior citizen" refers to a person 65 years of age or older.

[0060] Examples

[0061] The present invention will be more easily understood by reference to the following examples, which are only used to illustrate some aspects and embodiments of the present invention and are not intended to limit the present invention.

[0062] Unless otherwise specified, the materials used in this example are all commercially available materials or conventional materials.

[0063] Experimental animals

[0064] Zebrafish were all raised in fish culture water at 28 °C (water quality: 200 mg of instant sea salt was added to every 1 L of reverse osmosis water, the conductivity was 450 - 550 μS / cm; the pH was 6.5 - 8.5; the hardness was 50 - 100 mg / L CaCO3), provided by the fish culture center of Huante Biotechnology Co., Ltd. The experimental animal use license number is: SYXK(Zhe)2022 - 0004, and the feeding management meets the requirements of international AAALAC certification (certification number: 001458), and the IACUC ethical review number is: IACUC - 2025 - 202510290009 - 01.

[0065] Instruments, consumables and reagents

[0066] Dissecting microscope (SZX7, OLYMPUS, Japan);

[0067] Zebrafish behavior analysis system (Zebra Lab 3.22.3.31, Viewpoint, France);

[0068] 150 mm * 25 mm petri dish (Orange Scientific, Belgium);

[0069] 6-well plate (Zhejiang Beilanbo Biotechnology Co., Ltd., China);

[0070] 96-well plate (Nest Biotech, China);

[0071] Trinitrobenzenesulfonic acid (TNBS, lot number SLCN9362, Sigma, USA);

[0072] Dimethyl sulfoxide (DMSO, lot number BCCD8942, Sigma, Switzerland);

[0073] The medium- and long-chain fatty acid triglycerides were derived from medium- and long-chain fatty acid edible oil (production batch number 20250804) supplied by Yihai Kerry, with a purity of 61%.

[0074] The hydrolyzed protein is a partially hydrolyzed whey protein derived from Hilmar PROtelyzeAdvance (with a degree of hydrolysis in the range of 7%-15%) provided by Galaxy Ventures.

[0075] Prednisolone, white powder, batch number C10016501, purchased from Shanghai Maclean Biochemical Technology Co., Ltd., solvent is DMSO.

[0076] Evaluation of the efficacy of the sample in improving colic

[0077] Wild-type AB strain zebrafish (3 dpf) were randomly selected and placed in culture dishes. Except for the normal control group, all experimental groups were treated with 2,4,6-trinitrobenzenesulfonic acid (TNBS) in water to establish a zebrafish colic model. After treatment at 28℃ for 2 days, the TNBS was removed and the zebrafish were distributed into 6-well plates, with 30 zebrafish treated in each well (experimental group). Samples were administered in water (concentrations shown in Table 1). The positive control group received prednisone at a concentration of 15.0 μg / mL. A normal control group and a model control group were also included, with a volume of 3 mL per well. After another 2 days of treatment at 28℃, 10 zebrafish were randomly selected from each group and placed in a behavioral analyzer for 1 h. The total movement distance of the zebrafish was analyzed, and the statistical analysis results of this index were used to evaluate the efficacy of the samples in improving colic. Statistical results are expressed as mean ± SE. Statistical analysis was performed using SPSS software; p < 0.05 indicated statistical significance.

[0078] Then, for each embodiment and comparative example, the increase in total movement distance (mm) compared to the model control group was calculated (denoted as A). Furthermore, for each embodiment and comparative examples 7-9, the sum of the increases in total movement distance (mm) compared to the model control group for each corresponding example was calculated (denoted as B). For example, for Example 1 (partially hydrolyzed protein concentration 188 μg / mL + MLCT concentration 50 μg / mL), the "sum of the increase in total movement distance compared to the model control group for each corresponding example" is the sum of the "increase in total movement distance compared to the model control group" for Comparative Example 4 (partially hydrolyzed protein 188 μg / mL) and Comparative Example 1 (MLCT 50 μg / mL). Finally, the synergy coefficient (C=A / B) was calculated. When the synergy coefficient > 1, a synergistic effect exists; the larger the value, the stronger the synergistic effect.

[0079] Following the above method, zebrafish were administered partially hydrolyzed protein and MLCT at different ratios to evaluate their efficacy in improving intestinal colic. The dosages are shown in Table 1. The results are also shown in Table 1. Figure 1 and Figure 2 As shown.

[0080] Table 1. Experimental results evaluating the efficacy of the samples in improving intestinal colic.

[0081]

[0082] Note: Compared with the model control group, * indicates p < 0.05, ** indicates p < 0.01, and *** indicates p < 0.001;

[0083] Compared with Comparative Example 1, ! indicates p < 0.05, !! indicates p < 0.01, and !!! indicates p < 0.001;

[0084] Compared with Comparative Example 2, ## indicates p < 0.01;

[0085] Compared with Comparative Example 4, $$ indicates p < 0.01, and $$$ indicates p < 0.001;

[0086] Compared with Comparative Example 5, && indicates p < 0.01;

[0087] Compared with Comparative Example 6, + indicates p < 0.05.

[0088] From Table 1, Figure 1 and Figure 2The results showed that, compared with the normal control group, the total movement distance of wild-type AB strain zebrafish in the model control group after 3 dpf water-soluble administration of TNBS was significantly reduced (P < 0.05), indicating that the TNBS-induced intestinal colic model was successfully established. The positive control drug (prednisone), single-component partially hydrolyzed protein (375 μg / mL and 750 μg / mL), single-component MLCT (250 μg / mL and 1250 μg / mL), Examples 1-5, and Comparative Examples 7-9 all significantly improved intestinal colic, specifically by significantly increasing the total movement distance compared with the model control (P < 0.05).

[0089] Example 1 (MLCT to partially hydrolyzed protein weight ratio of 0.27) is equivalent to a combination of Comparative Example 1 (single-component MLCT 50 µg / mL) and Comparative Example 4 (single-component partially hydrolyzed protein 188 µg / mL). Compared with the model control group, the increase in total motility distance in Example 1 was 1591 mm, while the increases in total motility distance in Comparative Examples 1 and 4 were 239 mm and 191 mm, respectively. The former was greater than the sum of the latter two (430 mm), with a synergy coefficient of 3.7, indicating that Example 1 has a synergistic effect in improving intestinal colic. Similarly, Examples 2-5 also showed a synergistic effect in improving intestinal colic, while Comparative Examples 7-9 did not show a synergistic effect.

[0090] Furthermore, Examples 1, 2, and 3 (MLCT to partially hydrolyzed protein weight ratio of 0.067-0.27) had a larger synergistic coefficient than Examples 4 and 5 (MLCT to partially hydrolyzed protein weight ratios of 0.67 and 1.33, respectively), indicating that the synergistic effect of the two on improving intestinal colic was more significant at this weight ratio.

[0091] Furthermore, Examples 1 and 2 (MLCT to partially hydrolyzed protein weight ratio of 0.13-0.27) had a larger synergistic coefficient than Examples 3-5 (MLCT to partially hydrolyzed protein weight ratios of 0.067, 1.33 and 0.67, respectively), indicating that the synergistic effect of the two on improving intestinal colic was more significant at this weight ratio.

[0092] Evaluation of the efficacy of the sample in improving abdominal distension

[0093] Wild-type AB strain zebrafish (3 dpf) were randomly selected and placed in culture dishes. Except for the normal control group, all experimental groups were treated with TNBS dissolved in water. After treatment at 28℃ for 2 days, the TNBS was removed and the zebrafish were distributed into 6-well plates, with 30 zebrafish treated in each well (experimental group). Water-dissolved samples (concentrations shown in Table 2) were used as examples / comparative examples, and prednisone 15.0 μg / mL was used as a positive control. A normal control group and a model control group were also set up, with a volume of 3 mL per well. After further treatment at 28℃ for 2 days, 10 zebrafish from each group were randomly selected, photographed under a dissecting microscope, and the images were saved. Data were collected using NIS-Elements D 3.20 advanced image processing software, and the intestinal lumen area of ​​the zebrafish was analyzed. The statistical analysis results of this index were used to evaluate the efficacy of the samples in improving abdominal distension in zebrafish. Statistical results are expressed as mean ± SE. Statistical analysis was performed using SPSS software; p < 0.05 indicated statistical significance.

[0094] Then, the reduction in intestinal lumen area (pixels) compared to the model control group was calculated; and for each embodiment and comparative examples 7-9, the sum of the reductions in intestinal lumen area (pixels) of the corresponding comparative examples compared to the model control group was calculated; subsequently, the synergy coefficient was calculated as described above.

[0095] Following the above method, zebrafish were administered partially hydrolyzed protein and MLCT at different ratios to evaluate their efficacy in improving abdominal distension. The dosages are shown in Table 2. The results are also shown in Table 2. Figure 3 and Figure 4 As shown.

[0096] Table 2. Experimental results evaluating the efficacy of the samples in improving abdominal distension.

[0097]

[0098] Note: Compared with the model control group, * indicates p < 0.05, ** indicates p < 0.01, and *** indicates p < 0.001;

[0099] Compared with Comparative Example 1, !! indicates p < 0.01, and !!! indicates p < 0.001;

[0100] Compared with Comparative Example 2, ## indicates p < 0.01;

[0101] Compared with Comparative Example 4, $ indicates p < 0.05, and $$ indicates p < 0.01;

[0102] Compared with Comparative Example 5, && indicates p < 0.01;

[0103] Compared with Comparative Example 6, + indicates p < 0.05.

[0104] From Table 2, Figure 3 and Figure 4 The results showed that, compared with the normal control group, the intestinal lumen area of ​​wild-type AB zebrafish in the model control group after induction with TNBS water-soluble administration was significantly increased (P < 0.05), indicating successful modeling. The positive control drug (prednisone), single-component partially hydrolyzed protein (375 μg / mL and 750 μg / mL), and single-component MLCT (250 μg / mL and 1250 μg / mL) all significantly improved abdominal distension, specifically manifested as a significant decrease in intestinal lumen area (pixels) compared with the model control (P < 0.05).

[0105] Example 1 (MLCT to partially hydrolyzed protein weight ratio of 0.27) is equivalent to a combination of Comparative Example 1 (single-component MLCT 50 µg / mL) and Comparative Example 4 (single-component partially hydrolyzed protein 188 µg / mL). Compared with the model control group, Example 1 showed a reduction of 7535 pixels in intestinal lumen area (pixels), while Comparative Examples 1 and 4 showed reductions of 2888 pixels and 3082 pixels, respectively. The former was greater than the sum of the latter two (5970 pixels), with a synergy coefficient of 1.262, indicating a synergistic effect of Example 1 in improving abdominal distension. Similarly, Examples 2, 4, and 5 also showed a synergistic effect in improving abdominal distension, while Comparative Examples 7-9 did not show a synergistic effect.

[0106] Furthermore, Examples 1 and 2 (MLCT to partially hydrolyzed protein weight ratio of 0.13-0.27) had a larger synergistic coefficient compared to Examples 4 and 5 (MLCT to partially hydrolyzed protein weight ratios of 1.33 and 0.67, respectively), indicating that the synergistic effect of the two on improving bloating was more significant at this weight ratio.

[0107] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, and not to limit them; although the present invention has been described in detail with reference to the foregoing embodiments, those skilled in the art should understand that modifications can still be made to the technical solutions described in the foregoing embodiments, or equivalent substitutions can be made to some of the technical features; and these modifications or substitutions do not cause the essence of the corresponding technical solutions to deviate from the spirit and scope of the technical solutions of the embodiments of the present invention.

Claims

1. A nutritional composition comprising partially hydrolyzed protein and medium- and long-chain fatty acid triglycerides, wherein the weight ratio of the medium- and long-chain fatty acid triglycerides to the partially hydrolyzed protein is 0.067-1.33, wherein the partially hydrolyzed protein is selected from partially hydrolyzed whey protein, and wherein the degree of hydrolysis of the partially hydrolyzed protein is 7%-25%.

2. The nutritional composition according to claim 1, wherein the weight ratio of the medium- and long-chain fatty acid triglycerides to the partially hydrolyzed protein is 0.13-1.

33.

3. The nutritional composition according to claim 1, wherein the weight ratio of the medium- and long-chain fatty acid triglycerides to the partially hydrolyzed protein is 0.067-0.

27.

4. The nutritional composition according to claim 1, wherein the weight ratio of the medium- and long-chain fatty acid triglycerides to the partially hydrolyzed protein is 0.13-0.

27.

5. The nutritional composition according to claim 1, wherein the degree of hydrolysis of the partially hydrolyzed protein is 7%-17%.

6. The nutritional composition according to claim 1, wherein the degree of hydrolysis of the partially hydrolyzed protein is 7%-15%.

7. A product comprising the nutritional composition according to any one of claims 1-6.

8. The product according to claim 7, wherein the product is a drug.

9. The product according to any one of claims 7-8, characterized by The product contains 0.1%-50% partially hydrolyzed protein and 0.1%-30% medium- and long-chain fatty acid triglycerides, based on the total dry weight of the product.

10. Use of the nutritional composition according to any one of claims 1-6 in the preparation of a product for improving intestinal colic and / or bloating.

Images